|
|
Issuer: Mainz BioMed N.V.
/ Key words: Conference
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
07.05.2024 / 14:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Mainz Biomed to P... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Study results
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for NextGen CRC Test
25.04.2024 / 15:29 CET/CEST
The issuer is solely responsible for the content of... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Annual Results
Mainz Biomed Reports Full Year 2023 Financial Results
09.04.2024 / 14:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Mainz Biomed Reports Full Year 2023 Financial Results
ColoAlert® Rev... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Miscellaneous
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
19.03.2024 / 13:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Mainz Biomed Organizes HALLO DOC! Event to Highlight... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Miscellaneous
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer Exploring New Laboratory Diagnostic Options
18.03.2024 / 13:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Mainz Biomed: Webinar on Early Detection... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Miscellaneous
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in EvidenceBased Cancer Screening Innovations
12.03.2024 / 14:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Mainz Biomed Presen... Lire le communiqué |
|
| |
|
| |
|
|
Issuer: Mainz BioMed N.V.
/ Key words: Miscellaneous
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. GoToMarket Strategy for Next Generation Early Colorectal Cancer Diagnostic
05.03.2024 / 14:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
Main... Lire le communiqué |
|
| |
|
| |
